CORT

Corcept Therapeutics Inc.

FDA PDUFA Target Action Date

Saturday, July 11, 2026

46 days away

Drug Information

Drug Name: Relacorilant + nab-paclitaxel (CT.gov)
Application Type: NDA
FDA Designations: Orphan Drug
Indication: Platinum-resistant ovarian cancer (PROC)

Filing Details

Company: Corcept Therapeutics Inc. →
Stock Ticker: CORT
SEC CIK: 0001088856
Source: Company IR →

What is a PDUFA Date?

A PDUFA (Prescription Drug User Fee Act) date is the FDA's target deadline to complete review of a drug application. The FDA aims to make an approval decision by this date.

Standard Review: 10 months from filing acceptance
Priority Review: 6 months from filing acceptance
Possible Outcomes: Approval, Complete Response Letter (CRL), or extension

Explore Corcept Therapeutics Inc.

View Corcept Therapeutics Inc.'s full pipeline, approved drugs, and clinical trials.

View Pipeline → FDA Calendar →

Data sourced from SEC EDGAR filings. Last updated: 2026-04-10. Report an issue